GeoVax Clinical Data Aligns with IDSA Guidance on COVID-19 Vaccination for Immunocompromised Patients

The Infectious Diseases Society of America's recent guidance on COVID-19 vaccination for immunocompromised patients aligns with clinical findings from GeoVax Labs' Phase 2 studies of its GEO-CM04S1 vaccine candidate. The IDSA guidance, issued October 17, 2025, concluded that existing COVID-19 vaccines provide only moderate and short-lived protection for immunocompromised patients, with effectiveness against hospitalization ranging from 33% to 56% and waning within two months. The panel specifically called for new vaccine strategies tailored to vulnerable populations including cancer patients, transplant recipients, and individuals receiving immunosuppressive therapies.

GeoVax presented interim data from ongoing Phase 2 studies of GEO-CM04S1 at the World Vaccine Congress Europe 2025 in Amsterdam, demonstrating key findings that address the IDSA's concerns. The data showed robust T-cell responses to both Spike and Nucleocapsid antigens that exceeded responses seen with mRNA boosters. The vaccine also demonstrated broad, cross-variant immunity including activity against Omicron subvariants, along with a favorable safety profile characterized by only mild-to-moderate adverse events such as injection site reactions, fatigue, and myalgia, with no vaccine-related serious adverse events reported.

David A. Dodd, Chairman & CEO of GeoVax, emphasized the significance of these findings, stating that immunocompromised Americans represent one in eight adults and include cancer patients, transplant recipients, people with autoimmune disease, and those living with HIV. He noted that mainstream vaccine approaches, heavily centered on mRNA, continue to leave these populations without durable protection. The convergence of IDSA guidelines and GeoVax's clinical findings underscores the critical need for vaccine platforms that move beyond antibody-only strategies.

GEO-CM04S1 represents a multi-antigen, Modified Vaccinia Ankara-based COVID-19 vaccine designed specifically to elicit both antibody and T-cell immune responses. This dual-pathway activation is particularly important for patients who often fail to mount sufficient antibody responses with current mRNA vaccines. The vaccine's multi-antigen breadth, targeting both Spike and Nucleocapsid proteins, is intended to provide broader immunologic coverage and remain relevant as the virus continues to evolve. Ongoing trials include Phase 2 studies as a primary vaccine for immunocompromised individuals, including post-transplant and hematologic cancer patients, and as a booster for patients with chronic lymphocytic leukemia.

The clinical implications extend beyond immediate COVID-19 protection, addressing what Dodd described as both a moral imperative and national security necessity to protect over 40 million immunocompromised Americans. While mRNA vaccines were pivotal in the early pandemic response, their limitations in durability, breadth, and performance in immunocompromised populations highlight the risks of relying on a single platform. GEO-CM04S1 demonstrates how multi-antigen, T-cell-driven approaches can better protect high-risk populations and strengthen overall pandemic preparedness. Interim results across multiple studies consistently demonstrate that GEO-CM04S1 can generate broader, more durable protection than mRNA vaccines while maintaining a strong safety profile, particularly important for patients with hematologic malignancies where breakthrough infections remained mild-to-moderate.